Platelets obtained from some diabetic patients show enhanced in vitro platelet aggregation. This study sought to determine if platelets obtained from insulindependent diabetic subjects synthesize increased quantities of the labile aggregating substance, thromboxane A2 (TXA2), and if it may play a role in the enhanced platelet aggregation. Arachidonic acid (1 mM)-stimulated TXA2 synthesis, as determined via radioimmunoassay of its stable metabolite TXB2, was significantly greater (P < 0.01, N = 12) in platelet-rich plasma obtained from diabetics compared with matched controls. Arachidonic acid-stimulated TXB2 synthesis in the diabetic platelet-rich plasma was positively correlated with the ambient fasting plasma glucose (r = 0.61, P < 0.02, N = 15). Platelet aggregation induced by arachidonic acid (0.4–0.8 mM) was inhibited significantly less by 13-azaprostanoic acid (P < 0.04, N = 14), a competitive antagonist of the actions of prostaglandin H2 or TXA2 on platelets, compared with matched controls. The results support the notion that platelets obtained from some insulin-dependent diabetic subjects manifest increased synthesis of TXA2, which may contribute to the enhanced platelet aggregation.
Increased Platelet Arachidonic Acid Metabolism in Diabetes Mellitus
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
P V Halushka, R Mayfield, H J Wohltmann, R C Rogers, A K Goldberg, S A McCoy, C B Loadholt, J A Colwell; Increased Platelet Arachidonic Acid Metabolism in Diabetes Mellitus. Diabetes 1 November 1981; 30 (Supplement_2): 44–48. https://doi.org/10.2337/diab.30.2.S44
Download citation file: